Evaluation of two commercially-available vaccines on in the peripheral lymph nodes of experimentally-infected cattle

Background: Salmonella is a common inhabitant of the ruminant gastrointestinal tract, where it often resides asymptomatically and may be shed into the feces. More recently it was discovered that Salmonella may be contained within the peripheral, non-mesenteric lymph nodes, where it is impervious to...

Full description

Saved in:
Bibliographic Details
Main Authors: Thomas S. Edrington (Author), Terrance M. Arthur (Author), Guy H. Loneragan (Author), Kenneth J. Genovese (Author), Devin L. Hanson (Author), Robin C. Anderson (Author), David J. Nisbet (Author)
Format: Book
Published: SAGE Publishing, 2020-10-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_8c407a38233a4ec588790b054062ccc4
042 |a dc 
100 1 0 |a Thomas S. Edrington  |e author 
700 1 0 |a Terrance M. Arthur  |e author 
700 1 0 |a Guy H. Loneragan  |e author 
700 1 0 |a Kenneth J. Genovese  |e author 
700 1 0 |a Devin L. Hanson  |e author 
700 1 0 |a Robin C. Anderson  |e author 
700 1 0 |a David J. Nisbet  |e author 
245 0 0 |a Evaluation of two commercially-available vaccines on in the peripheral lymph nodes of experimentally-infected cattle 
260 |b SAGE Publishing,   |c 2020-10-01T00:00:00Z. 
500 |a 2515-1363 
500 |a 10.1177/2515135520957760 
520 |a Background: Salmonella is a common inhabitant of the ruminant gastrointestinal tract, where it often resides asymptomatically and may be shed into the feces. More recently it was discovered that Salmonella may be contained within the peripheral, non-mesenteric lymph nodes, where it is impervious to in-plant pathogen control interventions and may serve as a source of Salmonella -contamination of ground beef. Over the past 10 years considerable research effort has been expended at understanding how this pathogen gets to these lymph nodes, the duration of infection, and, most importantly, screening and developing potential intervention strategies that may be employed on farm prior to the animal being presented for slaughter. Methods: Utilizing an experimental model of Salmonella inoculation of bovine peripheral lymph nodes (PLNs), two pilot vaccine experiments were conducted to evaluate two Salmonella vaccines: Salmonella Newport Bacterial Extract (Experiment I) and Endovac-Bovi ® (Experiment II) on preventing Salmonella acquisition by these nodes. In Experiment I, 4 months following the booster vaccination, 30 steers were inoculated with three Salmonella serotypes intradermally: Newport, Montevideo, and Anatum administered to the right legs, left legs, and to the caudal thorax and abdomen, respectively. Cattle were inoculated every other day over the course of five days (three total inoculation events) and 6 and 12 days following the final Salmonella inoculation, 16 and 14 head in each treatment were euthanized, respectively. In Experiment II, 12 head of Holstein steers were utilized. Seven days following the booster and weekly thereafter for 3 weeks (four total inoculation events), cattle were inoculated as above and euthanized 7 days following final inoculation. Right and left sub-iliac, popliteal and pre-scapular lymph nodes were collected in each experiment, weighed and cultured for Salmonella . Results: In Experiment I, no treatment differences were observed in Salmonella prevalence 6 days post-inoculation (necropsy 1). However, in vaccinated cattle at the second necropsy, a reduction ( p  = 0.05) in Salmonella prevalence was observed in the sub-iliac and pre-scapular lymph nodes as well as when all nodes were evaluated collectively ( p  = 0.04). In Experiment II, the vaccine reduced ( p  = 0.03) Salmonella prevalence in the right popliteal and tended ( p  = 0.09) to decrease prevalence in both popliteal lymph nodes. Conclusion: Under these experimental conditions, the data generated provide evidence of a partial vaccine effect on Salmonella within PLNs and indicate that further research may be warranted. 
546 |a EN 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
690 |a Immunologic diseases. Allergy 
690 |a RC581-607 
655 7 |a article  |2 local 
786 0 |n Therapeutic Advances in Vaccines and Immunotherapy, Vol 8 (2020) 
787 0 |n https://doi.org/10.1177/2515135520957760 
787 0 |n https://doaj.org/toc/2515-1363 
856 4 1 |u https://doaj.org/article/8c407a38233a4ec588790b054062ccc4  |z Connect to this object online.